Other

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Cedars-sinai Medical Center

Maren Theresa Scheuner

Jerome I Rotter

Kent D Taylor

Huiying Yang

Cynthia Jorgensen

Muin J Khoury

Paula W Yoon

Family health history information can be used to assess familial risk for common diseases and determine early detection and prevention medical strategies. Assessed familial risk of disease can then be used to determine recommendations for disease prevention and screening that are targeted to familial risk. Other factors can be included to generate personalized disease prevention recommendations. For example, personal health history information, personal health behavior information, or both can be collected and assessed to generate personalized disease prevention recommendations based on the information collected. Recommendations for disease prevention and screening based at least on familial risk can be used to provide a personalized disease prevention plan that encourages a person to make behavior changes that will reduce the risk of disease and utilize preventive health services.

Personal assessment including familial risk analysis for personalized disease prevention plan

Personal and family health history information can be used to assess familial risk of disease. For example, information can be collected about the disease history of a person and the person's first- and second-degree relatives and then analyzed to determine the familial risk of common diseases such as coronary heart disease, stroke, type 2 diabetes, and colorectal, breast, and ovarian cancer. Assessed familial risk of disease can then be used by researchers to better estimate the contribution of personal history and family history to the etiology and natural history of a disease of interest, and by consumers and health professionals to determine recommendations for disease management, prevention and screening that are personalized and targeted to the familial risk. Other embodiments are also described and claimed.

Method and apparatus for determining familial risk of disease

In a method for detecting a genetic predisposition in a human for non-responsiveness to statin drug treatment for coronary artery disease, nucleic acids comprising nucleotide sequences of the human lipoprotein lipase (LPL) gene are amplified and analyzed. Homozygosity for a variant allele in a non-coding or untranslated region of the 3&prime; end of LPL, for example, LPL HindIII 2/2 or (TTTA),4/4 genotypes, is linked to non-responsiveness to treatment with statin drugs, including lovastatin, pravastatin, simvastatin, atorvastatin, fluvastatin, or cerivastatin. Oligonucleotide primer sequences, primer sets, and genetic testing kits allow the practitioner to practice the method and thus better individualize the treatment and improve the care of patients with coronary artery disease.

Genetic test to determine non-responsiveness to statin drug treatment

Growing community of inventors

Manhattan Beach, CA, United States of America

Maren Theresa Scheuner